AMR: IMIs Enable project reaches endpoints
The ENABLE project has achieved its initial goals to identify three antibacterial leads, select two antibacterial development candidates and advance one compound into Phase I development.
Author Archive for: TG
About Thomas Gabrielczyk
This author has yet to write their bio.Meanwhile lets just say that we are proud Thomas Gabrielczyk contributed a whooping 329 entries.
Entries by Thomas Gabrielczyk
MercachemSyncom, Bionetix, and ProQinase ink AML contract
28th January 2020 in News /by Thomas GabrielczykBionetix, ProQinase, and MercachemSyncom have announced that they will jointly develop a new AML drug, from target identification to clinical testing
iOnctura SA bags 15m in Series A round
27th January 2020 in News /by Thomas GabrielczykMerck KGaAs 2017 Swiss cancer spin-out iOnctura SA has raised 15m to bring its PI3K? inhibitor and autotaxin inhibitor to the clinic.
BioNTech acquires Neon at cheapest for $67m
17th January 2020 in News /by Thomas GabrielczykmRNA cancer neoantigen specialist BioNTech AG is set to buy all shares of Neon Therapeutics, Inc. expanding its pipeline of neoantigen-targeting therapies and getting foothold in the US.
New stromal target overcomes cancer resistance
16th January 2020 in News /by Thomas GabrielczykBritish researchers have identified several small molecule drugs that sensitized B cell cancers to chemotherapy and extended survival in mouse models.
Astellas and Adaptimmune team up in CAR-T development
15th January 2020 in News /by Thomas GabrielczykAdaptimmune Therapeutics plc and Japanese Astellas Pharma, Inc. have signed a discovery partnership to develop off-the-shelf allogeneic T cell-based cancer therapies from stem cells.
Illumina embraces Roche
14th January 2020 in News /by Thomas GabrielczykTwelve years after Roches $6.8bn hostile takeover bid for Illumina, the companies have entered into a 15-year partnership to boost personalised NGS-based cancer testing.
Incyte licenses Morphosys tafasitamab in US$2bn deal
13th January 2020 in News /by Thomas GabrielczykIncyte Corp. has signed a global license agreement for commercialisation of Morphosys AGs anti-CD-19 programme tafasitamab.
Novadiscovery takes off with 5 Series A financing
10th January 2020 in News /by Thomas GabrielczykIn silico clinical trials pioneer Novadiscovery SA has raised 5m in a series A financing led by Swiss Debiopharm Innovation Fund.
Alderaan Biotechnology raise 18.5m in Series A financing
9th January 2020 in News /by Thomas GabrielczykFollowing a 1.5m seed financing in 2017, cancer specialist Alderaan Biotechnology SAS has raised 18.5m in a Series A round led by Advent France Biotechnology and Medicxi.